Skip to main content

Table 1 Baseline characteristics for biologic disease-modifying antirheumatic drug-naïve (COAST-V study) and tumor necrosis factor inhibitor inhibitor-experienced (COAST-W study) patients

From: Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks

Baseline characteristics Patient groups
bDMARD-naïve (COAST-V study) (N = 341) TNFi-experienced (COAST-W study) (N = 316)
Age, years 41.7 (11.7)b 46.1 (12.4)
Male, n (%) 276 (81.2)b 253 (80.1)
Weight, kg 78.1 (15.8)b 83.2 (18.7)
Duration of r-axSpA symptoms, years 16.0 (10.3)b 18.4 (11.1)
Time since r-axSpA diagnosis, years 7.7 (8.4)b 11.6 (9.1)
C-reactive protein level, mg/L 13.5 (17.1)b 17.8 (26.6)
Therapy, n (%)
 Current cDMARD use (including MTX) 125 (36.8)b 86 (27.2)
 Current MTX use 29 (8.5)b 41 (13.0)
 Current SSZ use 97 (28.5)b 46 (14.6)
 IR to 1 TNFi 205 (65.1)e
 IR to 2 TNFi 78 (24.8)e
 Intolerance to TNFi 32 (10.2)e
ASDAS 3.8 (0.8)b 4.1 (0.8)
Disease activity and pain
 Patient global (disease activity) NRS 7.0 (1.6)b 7.9 (1.7)
 Spinal pain NRS 7.2 (1.5)b 7.9 (1.5)
 Spinal pain at night NRS 7.0 (1.6)b 7.7 (1.7)
Inflammation (BASDAI questions 5 and 6) 6.7 (1.7)b 7.3 (1.7)
Fatigue (fatigue NRS) 6.8 (1.7)b 7.3 (1.8)
Sleep (JSEQ) 8.2 (5.2)b 10.4 (5.6)
Reported part-time or full-time paid work, n (%) 252 ( 74.1)b 182 (57.6)
Work productivity (WPAI-SpA)
 Absenteeisma 10.9 (23.5)c 18.1 (27.2)f
 Presenteeisma 56.8 (21.0)d 60.7 ( 20.7)g
 Overall work impairment scorea 58.7 (22.0)d 64.4 (21.5)g
 Activity impairment 60.3 (19.8)b 70.7 (19.3)
  1. Data are presented as the mean with the standard deviation (SD) in parentheses, unless otherwise stated
  2. ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, cDMARD conventional disease-modifying antirheumatic drug, IR inadequate responder, JSEQ Jenkins Sleep Evaluation Questionnaire, MTX methotrexate, N number of patients in the analysis category, NRS numeric rating score, r-axSpA radiographic axial spondyloarthritis, SSZ sulfasalazine, TNFi tumor necrosis factor inhibitor, WPAI-SpA Work Productivity and Activity Impairment Questionnaire for Ankylosing Spondylitis
  3. aAbsenteeism, presenteeism, and overall work impairment were measured in patients reporting part- or full-time work
  4. bN = 340
  5. cN = 245
  6. dN = 234
  7. eN = 315
  8. fN = 167
  9. gN = 157